🔗 Share this article

An underground market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on communication apps, according to recent findings.

Experimental Drug Gaining Traction Via Social Media

Retatrutide, which remains in research studies, is being advertised by social media influencers for its alleged fat-burning effects. Viewers are urged to message these accounts directly for source information, while also receiving discount codes.

Active Commerce on Messaging Platforms

Separately, a robust market exists on messaging services, where communities with thousands of participants share “before and after” images, injection guides and claims of next-day UK delivery. Sellers promote the drug there before redirecting customers to other platforms for transactions.

Learning About The Experimental Drug

This medication is an experimental injection created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

However, doctors and pharmacists have warned that the sale of what is still an unapproved medication in the United Kingdom is worrisome and could lead to individuals administering products of unknown origin.

Several experts stated the popularity for retatrutide could be connected to the rising price of licensed weight loss products such as Mounjaro.

Legal Position and Enforcement

Marketing the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unapproved drug that must not be promoted or distributed for human use under the British medical regulations.

Several influencers try to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still breach pharmaceutical, marketing, and consumer regulations, risking penalties, prosecution or imprisonment.

Service Response and Content Removal

Based on the social media company, the platform has taken down violative content and prohibited related hashtags and search suggestions. The company stated it was committed to keeping the service secure and allocating resources in strengthening enforcement strategies.

Online Trading Operations

Research also found communities with up to nine thousand participants marketing the experimental drug using the platform's built-in discovery tool, which operates like a online catalog. Typing “retatrutide” immediately displays channels with thousands of members, filled with images of slimming results, positive reviews and detailed guides for mixing or injecting at residence.

Within moments of joining one group, a seller posted contact information, where most purchases take place. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about weight, medical conditions or previous experience.

Item Details and Pricing

Inside these groups, messages show black plastic parcels with Royal Mail stickers, claiming to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at residence with purified liquid, or ready-to-use injectors typically sold at 160 pounds for 20mg. When questioned how long a pen should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Service Moderation and Security Actions

A spokesperson for the messaging service stated it regularly monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering materials they cannot confirm. Even if the research behind this drug is valid, these online versions may not include what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs increasing, patients are turning to social media. But fake treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she explained.

Her staff has previously encountered individuals injured by self-injection from unverified suppliers. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is gambling with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.”

Manufacturer Statement

A spokesperson from Eli Lilly said retatrutide was in phase 3 research studies and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can market [it] for human use,” they explained, noting that any item “falsely representing itself as a company experimental substance not yet approved … may subject patients to possibly significant medical dangers”.